Are type-2 biomarkers of any help in asthma diagnosis?

To the Editor:

Asthma is a common chronic airway disease, the diagnosis of which remains challenging, as recently highlighted by the great proportion of both under- and overdiagnosis [1]. The current diagnosis is based on the conjunction of suggestive symptoms and the demonstration of an excessive airway calibre fluctuation either by a bronchodilation test or by a bronchial challenge [2, 3].

The majority of asthma patients encountered in daily practice are seen in primary care and are patients with mild disease [4]. Therefore, it is of critical importance to help primary care physicians to improve diagnostic accuracy. Spirometry is essential in making the diagnosis but, unfortunately, it is not often performed in the primary care setting in most European countries. Therefore, finding a suitable biomarker to help clinicians to make a correct asthma diagnosis has been considered as a priority of future research (European Asthma Research and Innovation Partnership) in the asthma field [5]. Although the question is of great interest, there are only a few studies that have carefully assessed the value of blood biomarkers in routine practice. In two single-centre, small-scale studies, serum IgE and blood eosinophil percentage were found to provide limited value in asthma diagnosis, yielding good or acceptable specificity but poor sensitivity [6, 7]. However, the airway inflammatory component of asthma may be conveniently appreciated by measuring the level of nitric oxide in exhaled air (FENO) [8]. This test yields immediate results and is totally noninvasive, which makes it a perfect contender to become a key test in clinical practice.

We investigated the utility of type-2 (T2) biomarkers in diagnosing asthma along with spirometry. To this end, we conducted a retrospective study on our large database including untreated patients referred to our asthma clinic by two dedicated respiratory physicians for chronic or episodic respiratory symptoms that may suggest asthma. We identified 702 patients who were without any maintenance treatment before the investigations at our asthma clinic from October 2004 till December 2019. The diagnosis of asthma was ascertained by lung function tests showing either significant reversibility to salbutamol (≥12% from baseline and 200 mL) and/or bronchial hyperresponsiveness to methacholine (provocative concentration causing a 20% fall in forced expiratory volume in 1 s (FEV₁) ≤8 mg·mL⁻¹) as recommended by the Global Initiative for Asthma. Therefore, asthma was excluded if the patient tested negative to both tests. The patients underwent a bronchodilating test, FENO measurement and blood sampling in the morning at visit 1, and a bronchial methacholine challenge 7–14 days later. Comparison between the asthmatic and nonasthmatic groups was performed by Mann–Whitney test. Predicting values of biomarkers and spirometric indices were assessed by receiver operating characteristic (ROC) curves from which the cut-off providing the best combined sensitivity and specificity was derived, together with the 95% sensitivity and specificity thresholds. Furthermore, we performed univariate and multivariate binary logistic regression to compare the capacity of the biomarkers and the spirometric indices, alone or in combination, to predict asthma. For each considered model, the corresponding ROC curve was derived.

The mean age of our patients was 51 years and 58% of our population were female. 57% were never-smokers, 24% were ex-smokers and 19% were current smokers. Median baseline FEV₁ was 95% predicted. Out of the 702 patients, 349 (49.7%) were diagnosed as having asthma while 353 (50.3%) tested negative to both bronchodilating test and bronchial challenge. Those diagnosed with asthma had a lower median (interquartile range) FEV₁ (90% (79–100%) versus 100% (91–110%) predicted, p<0.001) and

Cite this article as: Nekoee H, Graulich E, Schleich F, et al. Are type-2 biomarkers of any help in asthma diagnosis? ERJ Open Res 2020; 6: 00169-2020 [https://doi.org/10.1183/23120541.00169-2020].
TABLE 1 Performance of biomarkers and spirometry to diagnose asthma (upper part) and eosinophilic asthma (lower part)

|                                | Cut-off | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV | NPV | 95% sensitivity | 95% specificity |
|-------------------------------|---------|--------------|----------------------|----------------------|-----|-----|-----------------|-----------------|
| **Global population (n=702)** |         |              |                      |                      |     |     |                 |                 |
| $F_{ENO}$ ppb                 | 36      | 0.58 (0.54–0.62) | 0.30 (0.21–0.36) | 0.85 (0.78–0.89) | 0.55 | 0.66 | 6               | 72              |
| IgE kU·L$^{-1}$               | 132     | 0.57 (0.53–0.61) | 0.41 (0.32–0.46) | 0.78 (0.67–0.83) | 0.57 | 0.64 | 5               | 584             |
| Eosinophils %                 | 4.4     | 0.58 (0.54–0.62) | 0.23 (0.15–0.27) | 0.91 (0.83–0.94) | 0.54 | 0.72 | 0.8            | 5.9             |
| FEV₁ % predicted             | 96      | 0.67 (0.63–0.71) | 0.66 (0.57–0.72) | 0.62 (0.53–0.68) | 0.65 | 0.63 | 117             | 67              |
| FEV₁/FVC %                   | 76      | 0.67 (0.63–0.71) | 0.51 (0.42–0.57) | 0.76 (0.68–0.81) | 0.61 | 0.68 | 88              | 68              |

| **Population with successful sputum induction (n=561)** |         |              |                      |                      |     |     |                 |                 |
| $F_{ENO}$ ppb                 | 31      | 0.76 (0.71–0.82) | 0.64 (0.52–0.73) | 0.80 (0.61–0.86) | 0.91 | 0.42 | 10              | 81              |
| IgE kU·L$^{-1}$               | 135     | 0.68 (0.63–0.74) | 0.61 (0.47–0.68) | 0.73 (0.58–0.82) | 0.89 | 0.34 | 10              | 672             |
| Eosinophils %                 | 2.5     | 0.77 (0.72–0.81) | 0.80 (0.66–0.86) | 0.63 (0.52–0.69) | 0.93 | 0.33 | 1.30            | 6               |
| FEV₁ % predicted             | 90      | 0.60 (0.54–0.66) | 0.51 (0.39–0.61) | 0.66 (0.53–0.73) | 0.85 | 0.25 | 120             | 64              |
| FEV₁/FVC %                   | 74      | 0.64 (0.58–0.70) | 0.50 (0.39–0.60) | 0.86 (0.62–0.82) | 0.86 | 0.30 | 88              | 65              |

For the global population, 349 patients had asthma and for the population with successful sputum induction 104 had eosinophilic asthma (sputum ≥3%). AUC: area under the curve; NPV: negative predictive value; PPV: positive predictive value; $F_{ENO}$: exhaled nitric oxide fraction; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity.

median FEV₁/forced vital capacity (FVC) ratio (76% (70–82%) versus 81% (77–85%), p<0.001), and had a more frequent smoking history (27% and 22% ex-smokers and current smokers versus 20% and 15%, respectively). Patients who qualified as asthmatic displayed greater median levels of blood eosinophils (2.5% (1.4–4.0%) versus 1.8% (1.2–3.2%), p<0.001), serum total IgE (80 (19–247) versus 46 (18–121) kU·L$^{-1}$, p<0.001) and $F_{ENO}$ (22 (14–42) versus 18 (12–28) ppb, p<0.001). Among asthma patients in whom induced sputum was successful (n=288), there were 104 (37%) who displayed sputum eosinophils ≥3%.

When drawing ROC curves, blood eosinophils, IgE and $F_{ENO}$ provided areas under the curve (AUCs) <0.6 (table 1). The AUC for FEV₁ and FEV₁/FVC were slightly higher, reaching 0.67 for both the indices. None of the biomarkers nor the spirometric indices provided negative or positive predictive value >0.7 (table 1). In addition, the 95% sensitivity and specificity thresholds that can be used by the clinician to rule out or rule in an asthma diagnosis are provided in table 1.

After binary logistic regression, both $F_{ENO}$ and blood eosinophils were found to be significantly associated with asthma in all tested models (p<0.01 for both) while IgE was not. Our analysis also indicated that combining the three biomarkers did not increase the performance of the tests since the AUC remained at 0.6 (95 CI 0.56–0.64). However, when adding spirometric indices FEV₁ and FEV₁/FVC to T2 biomarkers, the AUC of the model rose to 0.72 (95 CI 0.68–0.75).

We further assessed the values of biomarkers to identify patients with eosinophilic asthma in the group of 561 patients with successful sputum induction. T2 biomarkers were good at predicting eosinophilic asthma (n=104) (table 1) with an AUC rising to 0.82 (95 CI 0.78–0.86) when all three biomarkers were combined. By contrast, adding FEV₁ and FEV₁/FVC did not improve AUC, which remained at 0.82.

To the best of our knowledge, our study including >700 untreated adult patients is the largest that has been reported so far. Another strength of our study is that asthma was carefully ascertained by lung function testing to confirm the diagnosis, so we are confident in our reference standard. The baseline demographics and baseline spirometric values of our population are representative of a mild asthma population, which is the most often encountered in daily practice. Our data indicate that using T2 biomarkers as index tests, either alone or in combination, fails to provide sufficient diagnostic accuracy in patients with suggestive symptoms of asthma. Overall, the T2 biomarkers provided good specificity but poor sensitivity, which is in keeping with small-scale studies on IgE [7] and blood eosinophils [6, 7], and with a recent meta-analysis on $F_{ENO}$ [9]. This observation also supports the concept that asthma may also be a non-T2 disease [8]. Though all belonging to the so-called T2 pathway, the three biomarkers we investigated have distinct regulation. It was important to investigate whether the combination of three biomarkers would improve accuracy, rather than each biomarker alone. However, our results show this not
the case. In our study the performance of T2 biomarkers, either alone or combined, was actually less than those of spirometric indices. This is not unexpected, as we can anticipate that excessive airway calibre fluctuation, which is the fundamental trait of asthma, may be more strongly related to other flow rate indices than to blood or airway inflammatory biomarkers.

Having said that, it does not deny the clinical value of measuring T2 biomarkers in phenotyping asthma, once the diagnosis has been done [10]. Indeed, there is accumulating evidence that the response to inhaled corticosteroids is dependent on the type of airway inflammation, with both sputum eosinophils [10, 11] and elevated $\text{FENO}$ [12, 13] being predictive of good treatment responses. We previously showed that combining $\text{FENO}$, blood eosinophils and IgE may help in identifying eosinophilic asthma in large and unselected populations with untreated and treated asthma [14]. Here, we show that $\text{FENO}$ and blood eosinophils both display an acceptable AUC (>0.75) with a very high negative predictive value (>0.9) to rule out eosinophilic asthma in untreated patients.

Finally, combining the three T2 biomarkers with both FEV$_1$ and FEV$_1$/FVC in the same model provided an AUC of 0.72, which is still well below what we could expect from a robust index test to help establishing an accurate diagnosis.

We conclude that relying on T2 biomarkers to make an asthma diagnosis in patients with suggestive symptoms lacks accuracy. The demonstration of excessive airway fluctuation by using reversibility or bronchial challenge remains essential. Using T2 biomarkers is an acceptable strategy to rule out eosinophilic asthma but not asthma by itself.

Haleh Nekoee$^1$, Emmanuel Graulich$^2$, Florence Schleich$^2$, Françoise Guissard$^2$, Virginie Paulus$^2$, Monique Henket$^2$, Anne Françoise Donneau$^1$ and Renaud Louis$^2$

$^1$Dept of Public Health, CHU Liege and University of Liege, Liege, Belgium. $^2$Dept of Pneumology, CHU Liege and University of Liege, Liege, Belgium.

Correspondence: Renaud Louis, Dept of Pneumology, CHU Liege and University of Liege, Avenue hippocrate, Liege 4020, Belgium. E-mail: r.louis@chuliege.be

Received: 6 April 2020 | Accepted after revision: 15 May 2020

Support statement: This study was supported by Federal Belgian Government EOS (Excellence of Science) grant EOS 30565447. Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of interest: H. Nekoee has nothing to disclose. E. Graulich has nothing to disclose. F. Schleich reports lecture and advisory board fees from GSK, AZ, Chiesi and Novartis, outside the submitted work. F. Guissard has nothing to disclose. V. Paulus has nothing to disclose. M. Henket has nothing to disclose. A.F. Donneau has nothing to disclose. R. Louis reports an educational grant and lecture fees from GSK, a research grant and advisory board fees from AZ, a research grant from Chiesi and a research grant and advisory board fees from Novartis, outside the submitted work.

References

1. Aaron SD, Vandemheen KL, Fitzgerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317: 269–279.
2. Global Initiative of Asthma. Global Strategy for Asthma Management and Prevention. 2019. Available from: www.ginasthma.org.
3. Louis R, Bougad N, Guissard F, et al. Bronchodilation test with inhaled salbutamol versus bronchial methacholine challenge to make an asthma diagnosis: do they provide the same information? J Allergy Clin Immunol Pract 2020; 8: 618–623.
4. Bloom CI, Nissen F, Douglas IJ, et al. Exacerbation risk and characterisation of the UK’s asthma population from infants to old age. Thorax 2018; 73: 313–320.
5. Garcia-Marcos L, Edwards J, Kennington E, et al. Priorities for future research into asthma diagnostic tools: a PAN-EU consensus exercise from the European asthma research innovation partnership (EARIP). Clin Exp Allergy 2018; 48: 104–120.
6. Hunter CI, Brightling CE, Woltmann G, et al. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121: 1051–1057.
7. Yurdakul AS, Dursun B, Canbakan S, et al. The assessment of validity of different asthma diagnostic tools in adults. J Asthma 2005; 42: 843–846.
8. Fahy JV. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol 2015; 15: 57–65.
9. Karrasch S, Linde K, Rucker G, et al. Accuracy of FENO for diagnosing asthma: a systematic review. Thorax 2017; 72: 109–116.
10. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet 2018; 391: 350–400.
11. Demarche SF, Schlech FN, Henket MA, et al. Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre. BMJ Open 2017; 7: e018186.

https://doi.org/10.1183/23120541.00169-2020
12 Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. *J Allergy Clin Immunol* 2015; 135: 877–883.
13 Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med* 2005; 172: 453–459.
14 Demarche SF, Schleich FN, Paulus VA, et al. Is it possible to claim or refute sputum eosinophils $\geq$ 3% in asthmatics with sufficient accuracy using biomarkers? *Respir Res* 2017; 18: 133.